{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:01:37Z","timestamp":1788951697204,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["214468"],"award-info":[{"award-number":["214468"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rmed.2025.108597","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:28:01Z","timestamp":1766017681000},"page":"108597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["TETRIS \u2013 Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis"],"prefix":"10.1016","volume":"251","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-7755","authenticated-orcid":false,"given":"Gernot","family":"Rohde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-2527","authenticated-orcid":false,"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-118X","authenticated-orcid":false,"given":"Kai-Michael","family":"Beeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-4820","authenticated-orcid":false,"given":"Peter","family":"Kardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Paulsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Watz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-920X","authenticated-orcid":false,"given":"Bernd","family":"Westermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharishini","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Claussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.108597_bib2","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/COPD.S371440","article-title":"Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States","volume":"17","author":"Sethi","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108597_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2025.108597_bib4","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2147\/COPD.S226601","article-title":"The IMPACT study - single inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI and UMEC\/VI in patients with COPD: efficacy and safety in a Japanese Population","volume":"14","author":"Kato","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108597_bib5","first-page":"43","article-title":"12-month prevalence of known chronic obstructive pulmonary disease (COPD) in Germany","volume":"2","author":"Steppuhn","year":"2017","journal-title":"J Health Monit"},{"key":"10.1016\/j.rmed.2025.108597_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/COPD.S291967","article-title":"Benefit\/risk profile of single-inhaler triple therapy in COPD","volume":"16","author":"Bourbeau","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"11","key":"10.1016\/j.rmed.2025.108597_bib7","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1007\/s12325-024-02982-y","article-title":"Striving for stability in patients with COPD: a new way forward?","volume":"41","author":"Han","year":"2024","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2025.108597_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable COPD treatment goal?","volume":"211","author":"Singh","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.108597_bib9","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","article-title":"Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis","volume":"39","author":"Ismaila","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2025.108597_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/COPD.S427770","article-title":"Real-world effectiveness of fluticasone furoate\/umeclidinium\/vilanterol once-daily single-inhaler triple therapy for symptomatic COPD: the ELLITHE non-interventional trial","volume":"19","author":"Beeh","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108597_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001585","article-title":"Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)","volume":"10","author":"Deslee","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.rmed.2025.108597_bib12","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.2147\/COPD.S382405","article-title":"Effectiveness of extrafine single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in Germany - the TriOptimize study","volume":"17","author":"Gessner","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108597_bib13","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108597_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106807","article-title":"Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study","volume":"197","author":"Mannino","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108597_bib15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2147\/COPD.S460903","article-title":"Evaluation of adherence and persistence to triple therapy in patients with COPD: a German claims data study","volume":"19","author":"Vogelmeier","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108597_bib16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/COPD.S424128","article-title":"Clinical concepts for triple therapy use in patients with COPD: a Delphi consensus","volume":"18","author":"Miravitlles","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108597_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12931-018-0865-1","article-title":"Primary data, claims data, and linked data in observational research: the case of COPD in Germany","volume":"19","author":"Mueller","year":"2018","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.108597_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000823","article-title":"Determinants of poor inhaler technique and poor therapy adherence in obstructive lung diseases: a cross-sectional study in community pharmacies","volume":"8","author":"Vanoverschelde","year":"2021","journal-title":"BMJ Open Respir Res"},{"issue":"11","key":"10.1016\/j.rmed.2025.108597_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11882-022-01041-2","article-title":"Narrative review of the role of patient-reported outcomes and inhaler handling errors in the control of asthma and COPD","volume":"22","author":"Guti\u00e9rrez","year":"2022","journal-title":"Curr. Allergy Asthma Rep."},{"issue":"S 01","key":"10.1016\/j.rmed.2025.108597_bib20","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1055\/s-0043-1761019","article-title":"Baseline patient demographics for TETRIS, a prospective, non-interventional study to characterize the use of triple therapy for COPD in Germany","volume":"77","author":"Claussen","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.rmed.2025.108597_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241287621","article-title":"Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany","volume":"18","author":"Vogelmeier","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108597_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","article-title":"Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials","volume":"21","author":"Ferguson","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108597_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/COPD.S184653","article-title":"Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population","volume":"14","author":"Bogart","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"5","key":"10.1016\/j.rmed.2025.108597_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","article-title":"Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain","volume":"162","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2025.108597_bib25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmed.2025.108597_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080409","article-title":"Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study","volume":"387","author":"Feldman","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2025.108597_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s12325-024-03088-1","article-title":"Comparative effectiveness of fluticasone furoate\/umeclidinium\/vilanterol and budesonide\/glycopyrrolate\/formoterol fumarate among US patients with chronic obstructive pulmonary disease","volume":"42","author":"Mannino","year":"2025","journal-title":"Adv. Ther."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125006602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125006602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:15Z","timestamp":1777595415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125006602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0954611125006602"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108597","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TETRIS \u2013 Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 GSK. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108597"}}